文献速递眼底病与葡萄膜炎

超高龄社会中新生血管性年龄相关性黄斑变性患病率与治疗负担的年龄特异性增长

Age-Specific Increases in the Prevalence and Treatment Burden of Neovascular Age-Related Macular Degeneration in a Super-Aged Society.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

该研究利用覆盖日本95%以上人口的国家医保索赔数据库,对比2014与2019年≥40岁人群新生血管性AMD的年龄别患病率与治疗负担。年龄标化患病率从101.3/10万升至152.4/10万,≥75岁人群增幅最大(62.9%),治疗索赔总量显著增加,主要由阿柏西普驱动。合并症与nAMD风险升高相关,但校正后2019年较2014年的风险升高未改变。

要点

  • 年龄标化nAMD患病率从2014年101.3/10万升至2019年152.4/10万。
  • 患病率在80-84岁达峰,但≥75岁人群增幅最大(62.9%)。
  • 治疗索赔总量显著增加,主要由阿柏西普驱动;各药物使用者平均给药次数仅小幅增加。

核心结论

  • 2014至2019年日本nAMD患病率与治疗负担大幅增加,超高龄人群中老年组的增长不成比例。
  • 合并症不能解释这一时间增长,提示除老龄化和合并症外还有其他因素推动负担上升。

研究设计与样本

  • 全国性重复横断面研究,使用日本国家医保索赔数据库(覆盖>95%人口)。
  • 纳入2014年和2019年≥40岁成人,估计年龄分层nAMD患病率。

主要发现

  • 2014年识别76,125例,2019年识别125,190例;年龄标化患病率从101.3升至152.4每10万人。
  • 两年患病率均在80-84岁达峰,但≥75岁人群增幅最大(62.9%)。
  • nAMD相关治疗索赔总量显著增加,主要驱动因素为阿柏西普;各药物使用者平均给药次数仅小幅增加。
  • 糖尿病、高血压和血脂异常与nAMD风险升高相关,但校正这些合并症后2019年较2014年的nAMD风险升高未改变。

临床怎么用

  • 在超高龄社会,应针对≥75岁人群加强nAMD筛查与治疗资源配置。
  • 合并症管理不能替代针对nAMD增长的其他防控措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To characterize age-specific changes in the prevalence and treatment burden of neovascular AMD (nAMD) from 2014 to 2019 in a super-aged society and to assess whether comorbidities contribute to this increase. METHODS: We performed a nationwide repeated cross-sectional study using Japan's national claims database (>95% population coverage). Adults aged ≥40 years in 2014 and 2019 were included to estimate age-stratified nAMD prevalence. Treatment burden was evaluated as the total number of nAMD-related treatment claims and mean administrations among users of each agent. Diabetes, hypertension, and dyslipidemia were identified from claims. Multivariable logistic regression compared nAMD cases with controls and assessed whether comorbidity adjustment attenuated the odds of nAMD in 2019 versus 2014. RESULTS: We identified 76,125 cases in 2014 and 125,190 in 2019; age-standardized prevalence increased from 101.3 to 152.4 per 100,000. Prevalence peaked at ages 80-84 in both years but increased most steeply among those ≥75 years (62.9%). Total treatment claims increased markedly, driven primarily by aflibercept. Among users of each agent, mean administrations increased modestly. Comorbidities were associated with higher odds of nAMD, but adjusting for them did not change the higher odds of nAMD in 2019 compared with in 2014. CONCLUSIONS: Between 2014 and 2019, the prevalence and treatment burden of nAMD increased substantially in Japan, with a disproportionate rise among older age groups in a super-aged population. Comorbidities did not account for the temporal increase, suggesting that factors beyond aging and comorbidity are contributing to the growing burden.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Akada M, Ideyama M, Kido A, et al. Age-Specific Increases in the Prevalence and Treatment Burden of Neovascular Age-Related Macular Degeneration in a Super-Aged Society. Invest Ophthalmol Vis Sci. 2026. PMID: 41960966. doi:10.1167/iovs.67.4.19

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。